Dr. R. Jeffrey Westcott, Medical Director at the Cardiac Cath Lab at the Swedish Heart and Vascular Institute, discusses the pharmacology of the new oral direct thrombin and Xa inhibitors, evaluates what patients are more likely to experience bleeding complications and discusses the advantages of these agents versus warfarin in treating patients with non-valvular atrial fibrillation.
